[1]王晓宁.芳香化酶抑制剂联合rhGH治疗男性特发性 矮小症患儿的疗效观察[J].国际内分泌代谢杂志,2019,39(05):298-301.[doi:10.3760/cma.j.issn.1673-4157.2019.05.003]
　Wang Xiaoning.Aromatase inhibitor combined with rhGH in the treatment of male children with idiopathic short stature[J].International Journal of Endocrinology and Metabolism,2019,39(05):298-301.[doi:10.3760/cma.j.issn.1673-4157.2019.05.003]
点击复制

芳香化酶抑制剂联合rhGH治疗男性特发性 矮小症患儿的疗效观察()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
39
期数:
2019年05期
页码:
298-301
栏目:
论著
出版日期:
2019-09-20

文章信息/Info

Title:
Aromatase inhibitor combined with rhGH in the treatment of male children with idiopathic short stature
作者:
王晓宁
广东省佛山市第二人民医院儿科 528000
Author(s):
Wang Xiaoning
Department of Paediatrics, The Second People's Hospital of Foshan City, Guangdong Province, Foshan 528000, China
关键词:
特发性矮小症;  青春期男孩;  芳香化酶抑制剂;  重组人生长激素
Keywords:
Idiopathic short stature;  Adolescent boy;  Aromatase inhibitor;  Recombinant human growth hormone
DOI:
10.3760/cma.j.issn.1673-4157.2019.05.003
摘要:
目的 探讨芳香化酶抑制剂联合重组人生长激素(rhGH)治疗男性特发性矮小症患儿的疗效和安全性。方法 将2014年1月-2016年1月广东省佛山市第二人民医院收治的36例特发性矮小症患儿纳入研究,均为青春期男孩,按照随机数字表法分为观察组(18例),接受来曲唑联合rhGH治疗,对照组(18例)仅接受rhGH治疗,疗程2年。比较治疗前、后两组患儿的身高、生长速度、骨龄、预测身高及治疗期间不良反应的发生情况。结果 治疗前,两组患儿的身高、生长速度、骨龄及预测身高相比差异均无统计学意义(P均>0.05),治疗2年后,两组患儿的身高、生长速度和预测身高较治疗前均显著升高(t观=3.167、2.794、4.129; t对=2.856、3.406、2.513,P均<0.05),且观察组患儿的身高、生长速度和预测身高均显著优于对照组(t=3.549、6.017、2.481,P均<0.05)。治疗后观察组的骨龄与对照组相比,差异无统计学意义(P>0.05),而且,两组的骨龄与治疗前相比,差异也均无统计学意义(P均>0.05)。在治疗期间,两组患儿均未出现严重的不良反应事件,其中观察组患儿不良反应的总发生率显著低于对照组(χ2=5.746,P<0.05)。结论 芳香化酶抑制剂联合rhGH治疗特发性矮小症效果明显,可有效改善患儿的身高和生长速度,且安全性较好。
Abstract:
Objective To investigate the clinical efficacy and safety of aromatase inhibitor combined with recombinant human growth hormone(rhGH)in the treatment of male children with idiopathic short stature.Methods Thirty-six children with idiopathic short stature admitted to the Second People's Hospital of Foshan City, Guangdong Province from January 2014 to January 2016 were included in the study. All patients were adolescent boys and were divided into observation group(n=18, treated with letrozole combined with rhGH), and control group(n=18, treated with rhGH alone)according to the random number table. The intervention lasted for two years. The height, growth rate, bone age, predicted height, and incidence of adverse reactions during treatment were compared between the two groups before and after treatment.Results Before treatment, there was no significant difference in the height, growth rate, bone age, and predicted height between the two groups(all P>0.05). After 2 years of treatment, the height, growth rate, and predicted height of children of the two groups were higher than before treatment(tobservation=3.167, 2.794, 4.129; tcontrol=2.856, 3.406, 2.513, all P<0.05). And the height, growth rate, and predicted height of the observation group were better than those of the control group(t=3.549, 6.017, 2.481, all P<0.05). After treatment, there was no significant difference in bone age between observation group and control group(P>0.05). Compared with before treatment, there was no significant difference in the bone age of the two groups after treatment(all P>0.05). During the period of treatment, there were no serious adverse events occurred in both groups. The total incidence of side effects in observation group was significantly lower than that in control group(χ2=5.746, P<0.05).Conclusion Aromatase inhibitors combined with rhGH is effective in the improvement of the height and growth rate of children with idiopathic short stature with high safety.

参考文献/References:

[1] Wong SC,Dobie R,Altowati MA,et al.Growth and the growth hormone-insulin like growth factor 1 axis in children with chronic inflammation: current evidence, gaps in knowledge, and future directions[J].Endocr Rev,2016,37(1):62-110.DOI:10.1210/er.2015-1026.
[2] Hackney AC,Davis HC,Lane AR.Growth hormone-insulin-like growth factor axis, thyroid axis, prolactin, and exercise[J].Front Horm Res,2016,47:1-11. DOI:10.1159/000445147.
[3] Ren S,Nie Y,Wang A.Effects of recombinant human growth hormone in the treatment of dwarfism and relationship between IGF-1, IGFBP-3 and thyroid hormone[J].Exp Ther Med,2016,12(6):3579-3582.DOI:10.3892/etm.2016.3831.
[4] Hezarjaribi A, Rezaeipour V, Abdollahpour R. Effects of intramuscular injections of vitamin E-selenium and a gonadotropin releasing hormone analogue(GnRHa)on reproductive performance and blood metabolites of post-molt male broiler breeders[J]. Asian Pacific J Reprod, 2016, 5(2):156-160.
[5] Loukianou E,Tasiopoulou A,Demosthenous C,et al.Pseudotumor cerebri in a child with idiopathic growth hormone insufficiency two months after initiation of recombinant human growth hormone treatment[J].Case Rep Ophthalmol Med,2016,2016:4756894.DOI:10.1155/2016/4756894.
[6] Mauras N,Ross JL,Gagliardi P,et al.Randomized trial of aromatase inhibitors, growth hormone, or combination in pubertal boys with idiopathic, short stature[J].J Clin Endocrinol Metab,2016,101(12):4984-4993.DOI:10.1210/jc.2016-2891.
[7] 赵强, 李志洁. 重组人生长激素治疗儿童生长激素缺乏症和特发性矮小症45例疗效观察[J]. 中国妇幼保健,2016,31(6):1300-1302. DOI:10.7620/zgfybj.j.issn.1001-4411.2016.06.70.
[8] 杜俊君.3～14岁矮小症患儿的病因分析[J].临床合理用药杂志,2017, 10(36):117-118. DOI:10.15887/j.cnki.13-1389/r.2017.36.058.
[9] 王平,蒋键波,杜姗,等.特发性矮小症患儿血清生长素、瘦素、胰岛素样生长因子、胰岛素样生长因子结合蛋白表达水平及意义[J].中华内分泌外科杂志,2016,10(2):163-165.DOI:10.3760/cma.j.issn.1674-6090.2016.02.014.
[10] 班博.特发性矮小症的诊断与治疗[J].济宁医学院学报,2017,40(2):77-81. DOI:10.3969/j.issn.1000-9760.2017.02.001.
[11] 孟晓波,朱华,于少飞,等.重组人生长激素治疗特发性矮小症患儿疗效及安全性研究[J]. 检验医学与临床,2017,14(18):2737-2739. DOI:10.3969/j.issn.1672-9455.2017.18.031.
[12] 金献江,罗越,吴慧平.促性腺激素释放激素类似物对特发性中枢性性早熟女童体质指数及骨代谢标志物水平的影响[J].中国全科医学,2016,19(9):1049-1052. DOI:10.3969/j.issn.1007-9572.2016.09.013.
[13] Azami M,Azadi T,Farhang S,et al.The effects of multi mineral-vitamin D and vitamins(C+E)supplementation in the prevention of preeclampsia: An RCT[J]. Int J Reprod Biomed(Yazd),2017,15(5):273-278.
[14] van der Steen M,Lem AJ,van der Kaay DC,et al.Insulin sensitivity and β-cell function in SGA children treated with GH and GnRHa: results of a long-term trial[J].J Clin Endocrinol Metab,2016,101(2):705-713.DOI:10.1210/jc.2015-3435.
[15] 孟晓波,朱华,于少飞,等.重组人生长激素治疗特发性矮小症患儿疗效及安全性研究[J]. 检验医学与临床,2017,14(18):2737-2739. DOI:10.3969/j.issn.1672-9455.2017.18.031.
[16] Dias JP,Veldhuis JD,Carlson O,et al.Effects of transdermal testosterone gel or an aromatase inhibitor on serum concentration and pulsatility of growth hormone in older men with age-related low testosterone[J].Metabolism,2017,69:143-147.DOI:10.1016/j.metabol.2017.01.025.
[17] Hawton K,Walton-Betancourth S,Rumsby G,et al.Growth hormone with aromatase inhibitor may improve height in CYP11B1 congenital adrenal hyperplasia[J].Pediatrics,2017,139(2):pii:e20160730.DOI:10.1542/peds.2016-0730.
[18] Pedrosa LF,de Oliveira JM,Thomé PRV,et al.Height increment and laboratory profile of boys treated with aromatase inhibitors with or without growth hormone[J].Horm Metab Res,2017,49(10):778-785.DOI:10.1055/s-0043-116944.
[19] Ferris JA,Geffner ME.Are aromatase inhibitors in boys with predicted short stature and/or rapidly advancing bone age effective and safe?[J].J Pediatr Endocrinol Metab,2017,30(3):311-317.DOI:10.1515/jpem-2016-0219.

备注/Memo

备注/Memo:
通信作者:王晓宁,Email:wangxiaoning018@163.com
Corresponding author: Wang Xiaoning, Email:wangxiaoning018@163.com
更新日期/Last Update: 2019-09-20